A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Evaluate Efficacy,
Safety and Pharmacokinetics after 2-weeks Administration of CPL207280 (GPR40 agonist)
in Subjects With Type 2 Diabetes (T2D)
Reset password
BioStat is responsible for data management and statistical analysis.